Gut microbiota-CRAMP axis shapes intestinal barrier function and immune responses in dietary gluten-induced enteropathy.

In the gut, cathelicidin-related antimicrobial peptide (CRAMP) has been largely described for its anti-infective activities. With an increasing recognition of its immune regulatory effects in extra-intestinal diseases, the role of CRAMP in gluten-induced small intestinal enteropathy celiac disease remains unknown. This study aimed to investigate the unexplored role of CRAMP in celiac disease. By applying a mouse model of gluten-induced enteropathy (GIE) recapitulating small intestinal enteropathy of celiac disease, we observed defective CRAMP production in duodenal epithelium during GIE. CRAMP-deficient mice were susceptible to the development of GIE. Exogenous CRAMP corrected gliadin-triggered epithelial dysfunction and promoted regulatory immune responses at the intestinal mucosa. Additionally, GIE-associated gut dysbiosis with enriched Pseudomonas aeruginosa and production of the protease LasB contributed to defective intestinal CRAMP production. These results highlight microbiota-CRAMP axis in the modulation of barrier function and immune responses in GIE. Hence, modulating CRAMP may represent a therapeutic strategy for celiac disease.

Problem

Celiac disease is a complex immune‐mediated small intestinal enteropathy, for which curative therapeutics are not available. Cathelicidin‐related antimicrobial peptide (CRAMP) plays an indispensable role in intestinal homeostasis. However, the effect of CRAMP in dietary gluten‐induced small intestinal enteropathy (GIE) such as celiac disease remains to be explored.

Results

Defective CRAMP production in duodenal epithelium was correlated with GIE development. CRAMP deficiency aggravated GIE, while exogenous CRAMP treatment protected against it. Furthermore, CRAMP harboured positive modulatory effect on intestinal barrier integrity by counteracting gliadin‐triggered epithelial dysfunction and promoted modulatory immune cell responses at the intestinal mucosa. Lastly, GIE‐associated enrichment of Pseudomonas aeruginosa and increased production of protease LasB contributed to defective intestinal CRAMP production.

Impact

This study provides novel evidence that CRAMP is a key regulatory mediator for GIE. Understanding the impact of gut microbiota‐CRAMP axis on intestinal barrier integrity and immune responses during GIE may shed light on novel therapeutic strategies for clinical celiac disease.

Introduction

Antimicrobial peptides (AMPs) or host defence peptides (HDPs) are evolutionarily conserved peptides as an essential innate defence mechanism found in most all living organisms (Zasloff, 2002; Gallo & Hooper, 2012). Apart from their classical antimicrobial activity, the immune modulatory capacity of AMPs has been increasingly appreciated and they may cause either pro‐inflammatory or anti‐inflammatory effects dependent on the disease model being investigated and their cellular source (Hancock et al, 2016). Among AMPs, we and others have particularly highlighted the role of cathelicidins [the sole member named LL‐37 in humans and cathelicidin‐related antimicrobial peptide (CRAMP) in mice] in autoimmune diseases. Commonly, neutrophil‐derived CRAMP, often citrullinated and when in excess, forms complexes with self‐nucleic acids to activate plasmacytoid dendritic cells (pDCs), inducing deleterious autoimmune responses (Diana et al, 2013; Kahlenberg & Kaplan, 2013). However, we previously demonstrated that pancreatic β‐cells‐derived CRAMP induces regulatory immune cells to shape pancreatic immune microenvironment, thereby protecting against autoimmune diabetes in non‐obese diabetic (NOD) mice (Sun et al, 2015).

Not surprisingly, the mammalian gut epithelium produces a diverse collection of AMPs, responding to the complex environmental cues in the intestine. In the gut, the role of cathelicidins has been largely confirmed to the large intestine for colonic inflammatory diseases or its anti‐infective activities (Mitsutoshi et al, 2005; Raqib et al, 2006; Hing et al, 2013; Mukherjee & Hooper, 2015). To a lesser extent, cathelicidin expression is found in the small intestine (Gallo et al, 1997; Mukherjee & Hooper, 2015). Despite an increasing recognition of its role in autoimmune disease contexts, the role of cathelicidins in the development of dietary gluten‐induced small intestinal enteropathy with autoimmune features such as celiac disease remains to be explored.

Here, we observe defective CRAMP production in duodenal epithelium of mice with gluten‐induced enteropathy (GIE). While CRAMP‐deficient (Cnlp −/−) mice are susceptible to the development of GIE, increasing duodenal CRAMP prevents GIE, by shaping intestinal barrier function and immune response. GIE‐associated dysbiosis with enhanced Pseudomonas aeruginosa (P. aeruginosa) contributes to CRAMP degradation via production of the protease LasB. Thus, the current study reveals a critical role of CRAMP in modulating GIE and supports future therapeutic strategy targeting CRAMP for the prevention of celiac disease.

Epithelial cathelicidin production is defective in dietary gluten‐induced enteropathy (GIE)

To test our hypothesis, we first determined the relevance of cathelicidin production and regulation with GIE in mice. In order to evaluate intestinal CRAMP expression and its effect on gluten‐induced small intestinal enteropathy, a mouse model of GIE by adoptive transfer of gliadin‐presensitized CD4+CD45RBlowCD25− T cells into lymphopenic Rag1 −/− mice, recapitulating intestinal pathology of human celiac disease (Freitag et al, 2009) was applied (Fig 1A). Serum CRAMP levels were found much lower in mice received gliadin‐presensitized T cells and fed with gluten‐containing diet (gluten group) than in those fed with gluten‐free diet (gluten‐free group; Fig 1B). Notably, we observed no difference in serum CRAMP levels in unsensitized mice fed with gluten‐free diet or gluten‐containing diet (Fig EV1A). Western blot experiment confirmed CRAMP expression in duodenum of Rag1 −/−, C57BL/6 and BALB/c mice but not of CRAMP‐deficient mice under steady state (Fig EV1B). After GIE induction, CRAMP became scarcely expressed both for the pro‐form (18 kDa) and the secreted mature form (5 kDa) in duodenal tissue and in ex vivo isolated duodenal epithelial cells (Fig 1C and D). CRAMP may be expressed by epithelial cells and by infiltrating immune cells (Gallo & Hooper, 2012). Immunofluorescent staining confirmed that CRAMP staining (red) was primarily localized in intestinal epithelium and co‐expressed with E‐cadherin‐positive cells, instead of Ly6G+ neutrophils or F4/80+ macrophages which were largely present in the lamina propria (Fig 1E). CRAMP expression by epithelial cells was reduced in mice fed with gluten diet, despite of increased Ly6G and F4/80 staining indicative of increased immune infiltrates. Lastly, we examined whether an association of serum LL‐37 levels, the human ortholog of CRAMP and susceptibility to clinical celiac disease could be established. Serum samples of celiac disease high‐risk subjects positive for anti‐tissue transglutaminase immunoglobulin A antibodies (anti‐tTG IgA) or/and anti‐deamidated gliadin peptide immunoglobulin G antibodies (anti‐DGP IgG)] and double‐negative subjects (anti‐tTG IgA− anti‐DGP IgG−) were obtained. Intriguingly, we found lower levels of serum LL‐37 in celiac disease high‐risk subjects than in double‐negative subjects (Fig EV1C). Together, these results suggest that CRAMP may play a role in GIE and prompt us to investigate how CRAMP modulates GIE development.

Figure 1

Epithelial CRAMP production is defective in dietary gluten‐induced enteropathy (GIE)

Animal protocol.

Serum CRAMP determination by ELISA (n = 8).

Western blot of pro‐form CRAMP and mature peptide in duodenum and ex vivo duodenal epithelial cells.

Localization and expression of CRAMP (red), E‐cadherin (green), F4/80 (green) and Ly6G (green) in duodenum by immunofluorescent staining. Representative photomicrographs of individual and merged staining were shown. Nuclei were stained with DAPI (blue). Scale bar: 50 μm.

Data information: Data in B were representative and were the mean ± SD from three independent experiments. Data (C–E) were representative from three independent experiments. P values were calculated by unpaired two‐tailed t‐test for comparison of two groups.

Source data are available online for this figure.

Figure EV1

The production of cathelicidin (CRAMP in mice and LL‐37 in humans) in mice and in human subjects. Related to Fig 1

Serum CRAMP determination by ELISA. Rag1 −/−/gluten‐free: unsensitized Rag1 −/−mice fed with gluten‐free diet. Rag1 −/−/gluten: unsensitized Rag1 −/− mice fed with gluten‐containing diet (n = 8).

Western blot of pro‐form CRAMP and the mature peptide in duodenum of Rag1 −/−, Cnlp −/− Rag1 −/−, C57BL/6 and BALB/c mice.

Serum LL‐37 determination by ELISA. Anti‐tTG IgA: anti‐tissue transglutaminase immunoglobulin A antibodies. Anti‐DGP IgG: anti‐deamidated gliadin peptides immunoglobulin G antibodies (Anti‐tTG IgA−Anti‐DGP IgG−, n = 50; Anti‐tTG IgA+Anti‐DGP IgG−, n = 46; Anti‐tTG IgA−Anti‐DGP IgG+, n = 50; Anti‐tTG IgA+Anti‐DGP IgG+, n = 13).

Data information: Data (A, C) were representative and were the mean ± SD from three independent experiments. Data in B were representative from three independent experiments. P values were calculated by unpaired two‐tailed t‐test for comparison of two groups (A) or one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons (C).

Source data are available online for this figure.

CRAMP deficiency potentiates GIE

As CRAMP production is defective during GIE development, we investigated the impact of CRAMP deficiency on GIE development. Classic symptoms of GIE include weight loss and duodenal histological changes (Freitag et al, 2009; Fig 2A). CRAMP‐deficient mice with GIE (Cnlp −/−/gluten group) exhibited worsened weight loss compared with control mice (gluten group; Fig 2B). Similarly, characteristic histological changes including duodenal crypt hyperplasia, villus atrophy and lymphocytic infiltration (Freitag et al, 2009) were exacerbated in CRAMP‐deficient mice induced with GIE (Cnlp −/−/gluten group; Fig 2C). Intestinal tight junction proteins (TJPs) locate at the apical ends of the lateral membranes of intestinal epithelial cells, including zona occludens‐1 (ZO‐1), ZO‐2, occludin and claudin‐1, and maintain the intestinal barrier integrity (Suzuki, 2013). Dysregulation of small intestinal TJPs leading to increased intestinal permeability is a key pathological event of GIE (Alessio, 2012). As shown in Fig 2D, loss of duodenal TJPs was exacerbated in Cnlp −/−/gluten group, compared with gluten group. Zonulin is a unique protein so far known to reversibly regulate intestinal permeability by modulating intercellular TJP expression (Amit et al, 2009; Alessio, 2012). Duodenal zonulin was found highly produced in Cnlp −/−/gluten group (Fig 2E), leading to suppressed TJP expression and increased intestinal permeability (Fig 2F). Collectively, CRAMP deficiency aggravates GIE.

Figure 2

CRAMP deficiency potentiates GIE

Animal protocol.

Changes in body weight relative to starting weight during 6 weeks (n = 6).

Left, representative images of duodenal damage by H&E staining. Scale bar: 200 μm. Right, graph depicted the ratio of the morphometric assessment of villus height to crypt depth (n = 6).

Western blot and densitometry analyses of duodenal tight junction proteins (claudin‐1, occludin, ZO‐1 and ZO‐2; n = 6).

Western blot and densitometry analysis of duodenal zonulin (n = 6).

Intestinal permeability was assessed by measuring FITC‐Dextran (n = 6).

Data information: Data (B–F) were representative and were the mean ± SD from three independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

Replenishing duodenal CRAMP is protective against GIE

We further investigated the effect of exogenous CRAMP treatment on GIE development. Mice were intraperitoneally administered with CRAMP (100 µg mouse−1 week−1) either two weeks before (prophylactic treatment) or 6 weeks after (therapeutic treatment) adoptive gliadin‐sensitized T cells transfer (Fig 3A). Small intestinal CRAMP levels were replenished following CRAMP administration (Figs 3B and EV2A and B). GIE‐associated weight loss was notably attenuated by both prophylactic and therapeutic treatment with CRAMP (Fig 3C). We found that increasing duodenal CRAMP protected against gluten‐induced gut barrier dysfunction as evidenced by improved histological markers (duodenum in Fig 3D, jejunum in Fig EV2C and ileum in Fig EV2D), increased expression of TJPs (duodenum in Fig 3E, jejunum in Fig EV2E and ileum in Fig EV2F), decreased duodenal zonulin production (Fig 3F) and reduced intestinal permeability (Fig 3G). Together, these data support a protective role of CRAMP for GIE by shaping intestinal barrier integrity.

Figure 3

Replenishing duodenal CRAMP is protective against GIE

Animal protocol.

Duodenal CRAMP determination by ELISA (n = 6).

Changes in body weight relative to starting weight during 6 weeks (n = 6).

Left, representative images of duodenal damage by H&E staining. Scale bar: 200 μm. Right, graph depicted the ratio of the morphometric assessment of villus height to crypt depth (n = 6).

Western blot and densitometry analyses of duodenal tight junction proteins (claudin‐1, occludin, ZO‐1 and ZO‐2; n = 6).

Western blot and densitometry analysis of duodenal zonulin (n = 6).

Intestinal permeability was assessed by measuring FITC‐Dextran (n = 6).

Data information: Data (B–G) were representative and were the mean ± SD from three independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

Figure EV2

Replenishing CRAMP is protective against jejunal and ileal barrier damage during GIE. Related to Fig 3

CRAMP determinations in (A) jejunum and (B) ileum by ELISA (n = 6).

Representative images of (C) jejunal and (D) ileal damage by H&E staining. Scale bar: 200 μm. The graphs depicted the ratio of the morphometric assessment of villus height to crypt depth (n = 6).

Western blot and densitometry analyses of tight junction proteins (claudin‐1, occludin, ZO‐1 and ZO‐2) in (E) jejunum and (F) ileum (n = 4).

Data information: Data were representative and were the mean ± SD from three (A–D) or two (E, F) independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

CRAMP counteracts gliadin‐triggered inflammatory signalling to protect epithelial function

Next, we attempted to decipher signalling mechanism underlying the regulatory effect of CRAMP on epithelial barrier function. Gliadin, the undigested immunogenic peptide from gluten, is known to induce prolonged epidermal growth factor receptor (EGFR) activation at Tyr1068, leading to downstream phosphoinositide‐3‐kinase/protein kinase B (Pi3K/Akt)‐nuclear factor kappa light chain enhancer of activated B cells (NF‐κB) signalling or a myeloid differentiation factor 88 (MyD88)‐dependent zonulin production, triggering epithelial barrier disruption (Thomas et al, 2006; Barone et al, 2007; Lammers et al, 2008; Yan et al, 2011). Then, using ex vivo isolated duodenal epithelial cells to investigate how CRAMP may affect gliadin‐triggered cellular signalling. We observed that CRAMP inhibited gliadin‐triggered phosphorylation of EGFR at Tyr1068, Pi3K/Akt activation, MyD88/TNF receptor‐associated factor 6 (TRAF6) expression and NF‐κB activation in duodenal epithelial cells ex vivo, while deficiency CRAMP intensified gliadin‐triggered inflammation (Fig 4A). Similarly, an inhibitory effect of LL‐37, the human ortholog of CRAMP, on pepsin/trypsin digested (PT)‐gliadin‐induced signalling was demonstrated on human epithelial cells (Fig 4B). To further determine the mechanism by which LL‐37 inhibits gliadin‐induced signalling, human epithelial cells were pre‐treated with Ilomastat before stimulation with PT‐gliadin. Ilomastat, an inhibitor of EGFR transactivation, was used to test whether LL‐37 acts via a competitive binding (Tjabringa et al, 2003; Sho et al, 2005). The results showed that the inhibitory effect of LL‐37 on PT‐gliadin‐induced signalling was abolished by Ilomastat (Fig 4B), supporting that CRAMP counteracts gliadin‐induced signalling by inducing a competitive binding to interrupt prolonged pathological activation of EGFR by gliadin.

Figure 4

CRAMP counteracts gliadin‐triggered inflammatory signalling to protect epithelial function

Western blot and densitometry analyses of gliadin‐triggered inflammatory signalling [p‐EGFR (Tyr1068), p‐Akt, Akt, MyD88, TRAF6, p‐p65 and p65] in epithelial cells ex vivo (n = 6).

Western blot and densitometry analyses of gliadin‐triggered inflammatory signalling [p‐EGFR (Tyr1068), p‐Akt, Akt, MyD88, TRAF6, p‐p65, p65 and zonulin] in vitro (n = 6).

Data information: Data (A and B) were representative and were the mean ± SD from three independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

CRAMP modulates intestinal immune disorder in GIE

In addition to barrier dysfunction, gliadin also triggers epithelial cell to release interleukin‐15 (IL‐15) which importantly activates intraepithelial lymphocytes (IELs) (Villella et al, 2019). IL‐15 activated IELs acquire cytotoxic properties by upregulating natural‐killer group 2 member D (NKG2D) receptor, responsible for epithelial cell damage, leading to dysregulated immune responses at intestinal mucosa in celiac disease (Qingsheng et al, 2006; Valérie & Bana, 2014). We examined whether CRAMP impacts on IL‐15 production and mucosal immune imbalance during GIE. Therapeutic treatment of cathelicidin significantly reduced Il15/IL15 expression in mouse duodenum and in human epithelial cells (Fig EV3A and B). Ex vivo examination also confirmed that CRAMP downregulated IL‐15 expression in duodenal epithelial cells (Fig 5A). Consequently, this led to attenuated percentage of NKG2D+ IELs (Fig 5B). The regulatory effect of CRAMP on IL‐15 production and cytotoxic IELs expansion was further confirmed by the observation that CRAMP‐deficient mice with GIE (Cnlp −/−/gluten group) exhibited a significantly increased percentage of NKG2D+ IELs (Fig 5B).

Figure EV3

Cathelicidin regulates cytokine expression in GIE and IL‐15 expression in PT‐gliadin‐stimulated human epithelial cells. Related to Fig 5

The mRNA levels of cytokines in duodenum were measured by RT–qPCR (n = 6).

The mRNA levels of IL15 in vitro were measured by RT–qPCR (n = 8).

Data information: Data were representative and were the mean ± SD from three (A) or four (B) independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

Figure 5

CRAMP modulates intestinal immune disorder in GIE

Il15 expression in duodenal epithelial cells ex vivo (n = 8).

The frequency of NKG2D+ IELs among CD3+CD4+ population (n = 8).

The frequency of CX3CR1+ macrophages in CD45+CD11b+ population and ALDH activity in CD45+CD11b+CX3CR1+ macrophages in lamina propria (n = 8).

The percentages of three subsets of CD45+CD11c+ DCs and ALDH activity in CD45+CD11c+ DCs in lamina propria (n = 8).

The percentages of (E) Foxp3+ Treg, (F) T‐bet+ Th1 and (G) RORγt+ Th17 among CD3+CD4+ population in lamina propria were shown by flow cytometry (n = 8).

Data information: Data in A were representative and were the mean ± SD from two independent experiments. Data (B–G) were representative and were the median ± interquartile range from three independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

Innate and adaptive immune cells in lamina propria (LP), including macrophages and dendritic cell (DCs) of different phenotypes as well as differentially polarized T cells, play important roles in development of celiac disease (Meresse et al, 2012). We observed that CRAMP induced CD45+CD11b+CX3CR1+ macrophages and conventional CD45+CD11c+DCs (cDCs) exhibiting a high aldehyde dehydrogenase (ALDH) activity (Fig 5C and D). CRAMP treatment stimulated the numbers of regulatory CD11b−CD103+ and CD11b+CD103+DCs and decreased inflammatory CD11b+CD103− DCs (Fig 5D). Accordingly, CRAMP treatment induced regulatory T cells (Treg) (Fig 5E) and reduced T helper 1 (Th1) (Fig 5F) and Th17 cells (Fig 5G). While restoring duodenal CRAMP harbours positive immunoregulatory effects, CRAMP deficiency further exacerbated gluten‐induced immune dysregulation (Fig 5A–G). Collectively, CRAMP shapes intestinal mucosal immune environment by decreasing cytotoxic NKG2D+ IELs and modulating DCs and macrophages phenotypes to induce regulatory T cells.

Gut dysbiosis contributes to CRAMP degradation

Finally, we aimed to determine why CRAMP production in epithelium is defective in GIE. Our as well as other groups have demonstrated that CRAMP expression may be regulated by gut microbiota and metabolites such as short‐chain fatty acids or proteases (Jan & Pike, 2009; Sun et al, 2015). Patients with celiac disease have altered faecal and duodenal microbiota compositions compared to healthy individuals, which is partially restored after treatment with a gluten‐free diet, suggesting the gut microbiota might play a vital role in celiac disease (Verdu et al, 2015). To test how GIE‐associated dysbiosis contributes to defective CRAMP production, we analysed gliadin‐induced perturbation of intestinal microbiota composition. Principal coordinates analysis (PCoA) showed that the gut microbiota communities in mice fed with gluten‐containing diet were remarkably different from gluten‐free diet group (Fig 6A). Analyses of microbiota composition at phylum level (Fig 6B), genus level (Fig 6C) and species level (Fig 6D) revealed that P. aeruginosa, an opportunistic pathogen unique to celiac disease patients and increased by gliadin (Caminero et al, 2019a), was increased, while Akkermansia muciniphila (A. muciniphila) was significantly decreased in gluten group. Butyrate‐producing bacteria did not show any significant change during GIE (Fig 6C), neither did faecal levels of short‐chain fatty acids (SCFAs) (Fig EV4). Pathogenic bacteria, including P. aeruginosa, are able to counteract host antimicrobial mechanism by producing proteases to cleave and inactivate cathelicidins (Jan & Pike, 2009; Cole & Nizet, 2016). Indeed, we found that the production of LasB, a protease of P. aeruginosa, was markedly increased in gluten group (Fig 6E). Moreover, at genus level, CRAMP was negatively associated with P. aeruginosa while positively correlated with A. muciniphila (Fig 6F). To confirm that P. aeruginosa could contribute to reduced CRAMP production, mice were orally supplemented with a highly virulent or a moderately virulent strain of P. aeruginosa, PA14 or PAO1 (Fig 6G and H). As shown in Fig 6I, reduced CRAMP production was observed in duodenum with colonization of the two P. aeruginosa strains, with a more pronounced effect observed with PA14. These data support that GIE‐associated gut dysbiosis with increased P. aeruginosa contribute to defective CRAMP production.

Figure 6

Gut dysbiosis contributes to CRAMP degradation

The unweighted (left) and weighted (right) UniFrac distances based on OTU abundance (NC: gluten‐free, M: gluten; n = 6).

The taxonomic composition distribution at phylum level (n = 6).

The taxonomic composition distribution at genus level (n = 6).

Duodenal colonizing P. aeruginosa and A. muciniphila as determined by RT–qPCR using bacterial‐specific species gene primers (n = 6).

The production of LasB (a protease of P. aeruginosa) was examined in duodenum (n = 6).

Dot plot of Pearson correlation coefficients among CRAMP, P. aeruginosa and A. muciniphila at species level. The size of each point represented the correlation coefficient and the colour represented positive (red) or negative (purple) relationship (n = 6).

Animal protocol.

Duodenal colonizing PA14 and PAO1 as determined by RT–qPCR using P. aeruginosa‐specific species gene primer (n = 9).

Western blot and densitometry analyses of pro‐form CRAMP and mature peptide in duodenum (n = 8).

Data information: Data (D, E, H, I) were representative and were the mean ± SD from three independent experiments. P values were calculated by unpaired two‐tailed t‐test for comparison of two groups (B–E) or one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons (H, I).

Source data are available online for this figure.

Figure EV4

Faecal content of short‐chain fatty acids in GIE. Related to Fig 6

Faecal levels of short‐chain fatty acids (acetic acid, propionic acid and butyric acid) were measured by gas chromatography–mass spectrometer (n = 6). Data were representative and were the mean ± SD from three independent experiments. P values were calculated by unpaired two‐tailed t‐test for comparison of two groups.

Source data are available online for this figure.

Pseudomonas aeruginosa depletion restores CRAMP production and dampens GIE

To finally confirm that gut dysbiosis favours defective CRAMP production and GIE development, we applied an antibiotic cocktail (ABX) to deplete mice of primary P. aeruginosa and increase A. muciniphila (Fig 7A) (Hill et al, 2010). We found that the ABX cocktail effectively reduced highly resistant pathogenic bacteria P. aeruginosa with an ability to cleave CRAMP, while keeping the beneficial bacteria, such as A. muciniphila intact (Fig EV5A–C), which consequently led to increased CRAMP production in serum (Fig 7B) and in duodenum (Fig 7C), supporting a direct effect of dysbiosis on duodenal CRAMP expression. Accordingly, ABX treatment alleviated the barrier damage (Fig 7D–F) and immune cell dysregulation in epithelium (Fig 7G) and lamina propria (Fig 7H–L) caused by gluten, reducing NKG2D+ IELs and promoting modulatory phenotypes of macrophages, DCs and T cells. Together, our results support that gut microbiota via intestinal CRAMP production, impact mucosal barrier and immune environment and thus the development of GIE.

Figure 7

Pseudomonas aeruginosa depletion restores CRAMP production and dampens GIE

Animal protocol.

The levels of CRAMP in serum (n = 8).

The levels of CRAMP in duodenum (n = 6).

Representative images of intestinal damage by H&E staining. Scale bar: 200 μm. The graph depicted the ratio of the morphometric assessment of villus height to crypt depth (n = 6).

Western blot and densitometry analyses of tight junction proteins (claudin‐1 and occludin) and zonulin in duodenum (n = 6).

Intestinal permeability was assessed by measuring FITC‐Dextran (n = 6).

The frequency of NKG2D+ IELs among CD3+CD4+ population (n = 8).

The frequency of CX3CR1+ macrophages among CD45+CD11b+ population (n = 8).

The percentages of three subsets of CD45+CD11c+ DCs (n = 8).

The percentages of (J) Foxp3+ Treg, (K) T‐bet+ Th1 and (L) RORγt+ Th17 among CD3+CD4+ population in lamina propria were shown by flow cytometry (n = 8).

Data information: Data (B–F) were representative and were the mean ± SD from three independent experiments. Data (G–L) were representative and were the median ± interquartile range from three independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

Figure EV5

The antibiotic cocktail treatment modulates gut microbiota composition, causing reduced P. aeruginosa and increased A. muciniphila during GIE. Related to Fig 7

Strain diversity (Left, Shannon’s diversity; Right, Chao1 index; Gluten‐free, n = 7; Gluten, n = 6; ABX/gluten, n = 6).

The taxonomic composition distributions at phylum (left) and genus (right) levels (Gluten‐free, n = 7; Gluten, n = 6; ABX/gluten, n = 6).

Duodenal colonizing P. aeruginosa and A. muciniphila as determined by RT–qPCR using bacterial‐specific species gene primers (n = 6).

Data information: Data in A were representative and were the mean ± SD. Data in C were representative and were the mean ± SD from three independent experiments. P values were calculated by one‐way ANOVA followed by Tukey’s post hoc test for multiple comparisons.

Source data are available online for this figure.

Discussion

Our study supports that perturbation of gut microbiota composition during GIE contributes to defective production of epithelial CRAMP. CRAMP promotes epithelial barrier integrity and function by counteracting gliadin‐triggered signalling. Additionally, CRAMP harbours positive immunoregulatory effects at intestinal mucosa by downregulating epithelial IL‐15 and promoting modulatory phenotypes of macrophages and DCs to induce Treg differentiation. Thus, a dysregulated immune‐gut microbiota axis triggered by gliadin results in low duodenal CRAMP levels, an unopposed mucosal barrier and immune dysregulation, and the development of GIE.

The mammalian gut epithelium produces a diverse collection of AMPs, to confront the complex microbial challenges. Although the small intestine is not considered as the primary site for cathelicidin production (Gallo & Hooper, 2012) compared to the colon, CRAMP is found to be expressed by small intestinal epithelial cells of adult mice (Gallo et al, 1997; Mukherjee & Hooper, 2015). Our data confirm its expression and secretion from epithelial cells in the duodenum of Rag1 −/−, BALB/c and C57BL/6 mice but not of CRAMP‐deficient mice (Fig EV1A). In addition, host immune state has a profound impact on gut microbiota (Wu & Wu, 2012). Upon induction of GIE immunopathology, distorted gut microbiota composition was observed three weeks after adoptive transfer of gliadin‐restricted T cells, accompanied by subsequently reduced CRAMP production, suggesting an immune‐gut microbiota axis to regulate endogenous antimicrobial peptide.

Effects of gliadin on epithelial dysfunction during GIE may be mediated via prolonged EGFR activation or a MyD88‐dependent mechanism to release zonulin (Thomas et al, 2006; Lammers et al, 2008). Gliadin triggered EGFR activation involves its phosphorylation at Tyr1068 (Barone et al, 2007), which leads to downstream Pi3K/Akt‐NF‐κB activation and inflammatory responses (Yan et al, 2011). Zonulin is the only protein known to date to reversibly regulate intestinal permeability by modulating intercellular TJPs (Amit et al, 2009). Gliadin‐induced zonulin release is thought to be mediated via C‐X‐C motif chemokine receptor 3 (CXCR3) and MyD88 signalling (Lammers et al, 2008), which enhances intestinal permeability, a key pathologic event of GIE. Indeed, it has been suggested that gliadin acts by prolonging binding and activation of EGFR by its native ligand EGF and delays receptor inactivation by interfering its endocytic pathway (Barone et al, 2007). Interestingly, cathelicidins (CRAMP or LL‐37) may also activate EGFR (Tjabringa et al, 2003; Sho et al, 2005; Niyonsaba et al, 2007; Sun et al, 2015) through a “trans‐activation” mechanism involving EGFR phosphorylation at a different tyrosine site (Sho et al, 2005). EGFR phosphorylation at different loci is associated with different cellular responses (Avraham & Yarden, 2011). Gliadin‐induced EGFR phosphorylation at Tyr1068 mediates intestinal dysfunction (Barone et al, 2007). In contrast, EGFR phosphorylation at Tyr100 induced by probiotic‐derived protein protects the intestinal barrier (Shen et al, 2018). While the exact mechanism remains to be determined, cathelicidin‐induced EGFR trans‐activation has been shown to depend on metalloproteinase (MMP)‐mediated HB‐EGF shedding and binding to EGFR (Tjabringa et al, 2003), which is in agreement with our observation that the inhibitory effect of LL‐37 on gliadin‐induced EGFR phosphorylation (Tyr1068) was abolished by a MMP inhibitor Ilomastat. Thus, LL‐37 counteracts gliadin‐induced signalling by inducing a competitive binding to interrupt prolonged pathological activation of EGFR by gliadin. In addition, earlier evidence has shown that LL‐37 inhibits MyD88 expression (Pinheiro et al, 2009). This agrees with our data that LL‐37 inhibits gliadin‐induced MyD88 expression, thus contributing to reduced zonulin production. Together, it may be postulated that LL‐37, by preventing gliadin‐induced EGFR Tyr1068‐phosphorylation associated with pathologic consequences and by inhibiting MyD88‐dependent zonulin, protects against gliadin‐induced epithelial dysfunction in GIE.

Another hallmark of celiac disease is NF‐κB‐regulated IL‐15 expression. IL‐15 may be released from epithelium upon its stimulation by gliadin (Valérie & Bana, 2014) and plays a critical role in IEL‐mediated epithelial cell damage and in dysregulated immune responses during celiac disease. IL‐15 is transcriptionally regulated by NF‐κB. The p65 subunit of NF‐κB binds to the IL‐15 NF‐κB motif (Villella et al, 2019). Additional, MyD88‐dependent signalling is important for regulation of IL‐15 production and in maintenance of IELs (Qingsheng et al, 2006). Cathelicidins have been shown to suppress the translocation of NF‐κB subunits (Mookherjee et al, 2006) as well as MyD88 expression. Consistently, we observed that cathelicidin antagonized gliadin‐induced NF‐κB activation and MyD88 signalling and suppressed epithelial IL‐15 production. Following its release from epithelial cells, IL‐15 activates intraepithelial lymphocytes responsible for epithelial cell damage (Valérie & Bana, 2014). Furthermore, IL‐15 treatment reversed the effect of retinoic acid (RA) by altering the tolerogenic phenotype of intestinal DCs, hence preventing the generation of inducible Treg cells to dietary gluten and promoting the development of Th1 and Th17 inflammatory immune responses (Valérie & Bana, 2014). Here, our data support that CRAMP reduces epithelial toxic NKG2D+ IELs by IL‐15 inhibition. Additionally, our data demonstrate that CRAMP induces ALDH+ macrophages and ALDH+ cDCs. ALDH is an important enzyme present in innate immune cells important for the production of RA, which is a key mechanism of these cells to induce Treg cells (Guilliams et al, 2010) and to inhibit the development of Th17 (Daniel et al, 2007). In addition, at intestinal mucosa, cDCs may be subdivided into three subsets based on the expression of CD11b and CD103: CD11b−CD103+, CD11b+CD103− and CD11b+CD103+ DCs, exhibiting inflammatory or modulatory properties. The CD11b+ CD103+DCs are so far found to be unique to the intestines and to preferentially drive the development of Foxp3+ Treg, which is dependent on RA (Denning et al, 2007; Sun et al, 2007). We observe that CRAMP induces the regulatory subsets of cDCs (CD11b−CD103+ and CD11b+CD103+) and reduces the inflammatory subsets (CD11b+CD103−), suggesting its additional immune modulatory mechanism. All these mechanisms contribute to regulatory T cells polarization induced by CRAMP.

Here, we demonstrate that a dysregulated immune‐gut microbiota axis contributes to epithelial CRAMP loss. To be noted, cathelicidin antimicrobial peptide is part of host defence mechanisms to exhibit broad‐spectrum activities against microbial invasions. Nevertheless, during co‐evolution with the host, opportunistic pathogens have also developed a variety of means to resist AMPs (Nizet, 2006). For examples, proteases of P. aeruginosa, Staphylococcus aureus, Streptococcus pyogenes, Porphyromonas gingivalis and Enterococcus faecalis lead to degradation of LL‐37 and consequently abolish antimicrobial activity (Jan & Pike, 2009). Celiac disease is associated with typical gut dysbiosis (Sanchez et al, 2013; Verdu et al, 2015), and the role of gut microbiota appears to be complex. Mice colonized with a microbiota devoid of opportunistic pathogens develop attenuated dietary gluten‐induced immunopathology compared with germ‐free mice and mice that harbour a complex microbiota that includes opportunistic pathogens (Galipeau et al, 2015). Specific gut bacteria may promote or protect celiac disease‐associated immunopathology (Caminero et al, 2019a; Caminero et al, 2019b). We observed that gut dysbiosis developed with induction of GIE, with increased P. aeruginosa and reduced A. muciniphila, which were similarly observed in clinical celiac disease (Bodkhe et al, 2019; Caminero et al, 2019a). Duodenal tissue was detected with increased abundance of P. aeruginosa, confirming its ability of translocating from colon to duodenum. Recently, the pathogenic mechanism of P. aeruginosa in celiac disease has been revealed (Caminero et al, 2016; Caminero et al, 2019a). In mice expressing celiac disease risk genes, the metabolite elastase, also called LasB of P. aeruginosa synergizes with gluten to induce severe inflammation (Caminero et al, 2019a). It is suggested that P. aeruginosa‐derived LasB promotes the propagation of celiac disease mediated by the protease‐activated receptor 2 (PAR2) pathway, which interacts with zonulin (Amit et al, 2009; Caminero et al, 2019a). Also, P. aeruginosa produces LasB with demonstrated ability to degrade CRAMP (Jan & Pike, 2009). Indeed, we observed increased LasB in duodenal tissue, corresponding to reduced CRAMP. We further confirmed this by applying antibiotic treatment able to deplete P. aeruginosa. Such treatment dampened the development of GIE, by preventing P. aeruginosa‐mediated degradation of CRAMP, confirming the role of gut dysbiosis in defective CRAMP production. The effect of antibiotic therapy in the development of GIE is complex, dependent on its targeted gut bacteria. Accordingly, selective antibiotic treatment targeting different bacterial subgroups may yield varying outcome on celiac disease (Hansen et al, 2013; Dydensborg Sander et al, 2019). Perinatal antibiotic treatment, which led to increased numbers of Proteobacteria, enhanced the severity of GIE. Vancomycin treatment that propagates A. muciniphila, reduces interferon‐gamma (IFN‐γ) and IL‐15 levels in the intestine and NKG2D ligand expression on intestinal epithelial cells (IECs), thus protecting GIE (Hansen et al, 2013). While P. aeruginosa is resistant to most antibiotics (Breidenstein et al, 2011), our combinatory antibiotics effectively reduce P. aeruginosa, which is attributable for its protective effect on GIE.

Altogether, in current GIE model we demonstrate that the undigested immunogenic gliadin from gluten triggers a dysregulated immune‐gut microbiota axis that negatively impacts intestinal CRAMP production, consequently inducing pathological dysregulation of barrier function and immune environment at intestinal mucosa and unopposed development of GIE. It should be interesting to determine in other experimental models of celiac disease and in susceptible individuals whether similar effect and mechanism of CRAMP exist. Finally, our data support that manipulation of gut microbiota and the production of intestinal AMPs may represent an attractive therapeutic strategy to maintain intestinal homeostasis and prevent the development of celiac disease.

Materials and Methods

Reagents and Tools table

Methods and Protocols

Animals and treatments

All animal experimental protocols were approved by the Animal Ethics Committee of Jiangnan University [JN. No20181230c0500815(303) and JN. No20170614‐20190225 (77)] and were performed in accordance with the guidelines. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, 2010). Male C57BL/6 mice, Rag1 −/− mice (N000295; T004753; GemPharmatech Co., Ltd, Jiangsu, China), CRAMP‐deficient Cnlp −/− mice (C57BL/6 background; JAX:017799; The Jackson Laboratory, CA, USA) and Cnlp −/− Rag1 −/− mice were maintained at the Animal Housing Unit of Jiangnan University (Jiangsu, China) under a controlled temperature (23−25°C) and a 12 h light–12 h dark cycle. The Cnlp −/− Rag1 −/− mice were generated by backcrossing of Cnlp −/− mice with Rag1 −/− mice for more than 10 generations. All experiments were performed with mice at age 6–8 weeks.

To recapitulate gliadin‐induced small intestinal enteropathy and the gliadin‐specific T‐cell responses in active celiac disease patients, we chose an experimental model of dietary gluten‐induced enteropathy by adoptive gliadin‐specific T cells transfer as previously described (Freitag et al, 2009). Briefly, C57BL/6 donor mice were maintained on a gluten‐free standardized diet (AIN‐76A; Research Diets, NJ, USA) from birth. Mice were given 100 μg gliadin (G3375‐25G) or ovalbumin (negative control antigen) in Complete Freund’s Adjuvant at tail base on day 0 and 50 μg gliadin or ovalbumin in Incomplete Freund’s Adjuvant on day 14 (all Sigma, Shanghai, China). Rag1 −/− and Cnlp −/− Rag1 −/− recipient mice were changed to AIN‐76A on day 21. For sensitization, on day 28, Rag1 −/− and Cnlp −/− Rag1 −/− recipient mice were injected intraperitoneally with 4.5 × 105 splenic CD4+CD45RBlowCD25− T cells from C57BL/6 donor mice. Mice were divided randomly into experimental groups by different diet: gluten‐free diet (AIN‐76A) and gluten‐containing diet [based on AIN‐76A, containing 2.5 g wheat gluten (G5004‐500G; Sigma, Shanghai, China) per kg] (n = 6‐8). Unsensitized mice did not receive splenic CD4+CD45RBlowCD25− T cells and were fed with either gluten‐free diet or gluten‐containing diet. CRAMP (the mature form; 088328; GL biochem, Shanghai, China) was intraperitoneal administered (100 µg mouse−1 week−1) either two weeks before (prophylactic treatment) or 6 weeks after (therapeutic treatment) received adoptive T cells transfer. For antibiotic treatment (Hill et al, 2010), three weeks after adaptive transfer, mice were given 1 g l−1 metronidazole, 1 g l−1 gentamicin, 0.5 g l−1 vancomycin, 1 g l−1 ampicillin and 1 g l−1 neomycin (all in Sigma, Shanghai, China) by daily oral gavage of 200 μl in antibiotic solution (100% H2O) for 10 days (Hill et al, 2010). Mice were sacrificed by a lethal dose of pentobarbital sodium (90 mg kg−1; Sigma, Shanghai, China).

Human samples

This study was approved by the ethics committee of the Second Affiliated Hospital of Nanchang University [no. (2010) 041]. All subjects provided informed consent before participation and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. The characteristics of participants were given in Appendix Table S1.

Cell culture and treatment

Human intestinal epithelial cells Caco‐2 (HTB‐37) were obtained from the American Type Culture Collection (ATCC, VA, USA) and maintained in DMEM containing 1,800 mg l−1 NaHCO3, supplemented with 10% FBS, 100 U ml−1 penicillin and 100 μg ml−1 streptomycin at 37°C in a humidified atmosphere with 5% CO2. LL‐37 (GL biochem, Shanghai, China), a broad‐spectrum matrix metalloproteinase inhibitor Ilomastat (Selleck, Shanghai, China) and PT‐gliadin were dissolved in distilled water. For treatment, cells were pre‐incubated with Ilomastat (5 μM) for 1 h, subsequently stimulated with PT‐gliadin (1 mg ml−1) and LL‐37 (10 µg ml−1) for 3 h. Cells were then collected for measurements. All cell lines were regularly tested negative for mycoplasma contamination.

Bacterial supplementations

Pseudomonas aeruginosa PA14 (patient isolate) and PAO1 (47085; ATCC, WA, USA) were synthesized and kindly provided by Dr Lvyan Ma’s laboratory in Chinese Academy of Sciences (Beijing, China). Rag1 −/− mice were supplemented by oral gavage with P. aeruginosa PA14 or PAO1 three times a week for 2 weeks (1010 cfu mouse−1).

RNA isolation and reverse transcription real‐time quantitative polymerase chain reaction (RT–qPCR)

Total RNA was extracted from tissues and cells using TRIzol following the manufacturer’s protocol, and cDNAs were synthesized by a reverse transcription reagent kit (RR036A; TaKaRa, Kyoto, Japan). Gene expression levels were analysed by RT–qPCR using the Bio‐Rad CFX Connect Real‐Time System (CA, USA). After the preparation of the duodenal content (bacterial DNA extraction), the quantity of total bacteria, P. aeruginosa and A. muciniphila at species level were determined using bacterial‐specific species gene primers and bacterial 16S gene sequence universal primer. Primer sequences were given in Appendix Table S2.

Preparation of T cells fractions for adoptive transfer experiments

CD4+CD45RBlowCD25− subset T cells were isolated from spleens as described (Mottet et al, 2003). In brief, single cell suspensions were stained with biotinylated anti‐CD8a (130‐118‐147), CD11b (130‐113‐233), CD11c (130‐113‐578), CD19 (130‐113‐729), CD45R(B220) (130‐123‐853), CD49b(DX5) (130‐101‐934), CD105 (130‐101‐992), MHC Class II (130‐101‐849), Ter‐119 (130‐120‐828), TCRγ/δ (130‐114‐028) and CD25 (130‐092‐569) followed by streptavidin MACS beads (130‐048‐101) and sorted on an AutoMACS (all Miltenyi Biotec, Bergisch Gladbach, Germany). The CD4+CD25− fraction was then stained with anti‐CD45RB‐FITC (130‐102‐461), followed by incubation with anti‐FITC MACS beads (130‐048‐701) and sorted on an AutoMACS.

Statistical analyses

Data were expressed as mean ± SD. P < 0.05 was considered statistically significant. Difference between two groups was determined using unpaired two‐tailed t‐test. Differences among three or more groups were determined analysis of variance (ANOVA) followed by Tukey’s post hoc test. For flow cytometry statistical analyses, data were expressed as median ± interquartile range. The Pearson correlation coefficients between CRAMP and microbiota were analysed by the R Project (NJ, USA). All data were analysed using GraphPad Prism 8 software (CA, USA).

Author contributions

ZR, L‐LP and YH performed experiments and analysed data. HC and YL helped with obtaining the human samples. HL, XT, YL, BL, XD and XP assisted the experiments. YF and HFL helped with bacteria culture. BA and JD contributed to the data acquisition and critically reviewed the manuscript. ZR, JS and JD designed and interpreted experiments. JS, ZR and L‐LP wrote the paper.

Conflict of interest

The authors declare that they have no conflict of interest.

Appendix

Click here for additional data file.

Expanded View Figures PDF

Click here for additional data file.

Source Data for Expanded View

Click here for additional data file.

Review Process File

Click here for additional data file.

Source Data for Figure 1

Click here for additional data file.

Source Data for Figure 2

Click here for additional data file.

Source Data for Figure 3

Click here for additional data file.

Source Data for Figure 4

Click here for additional data file.

Source Data for Figure 5

Click here for additional data file.

Source Data for Figure 6

Click here for additional data file.

Source Data for Figure 7

Click here for additional data file.

Reagent/Resource	Reference or Source	Identifier or Catalog Number
Experimental Models
Mouse: C57BL/6J:	GemPharmatech	C57BL/6JGpt; Cat# N000295; RRID: SCR_017239
Mouse: Cnlp −/−:	Jackson Laboratory	B6.129X1‐Camptm1Rlg/J Mus musculus; Cat# JAX:017799; RRID: IMSR_JAX:017799
Mouse: Rag1 −/−:	GemPharmatech	B6/JGpt‐Rag1em1Cd /Gpt; Cat# T004753; RRID: SCR_017239
Mouse: Cnlp −/− Rag1 −/−	This study	N/A
Cell lines: Caco‐2	ATCC	Cat# HTB‐37; RRID: CVCL_0025
Patient samples: Human serum	Second Affiliated Hospital of Nanchang University	Ethics number: no. [2010] 041
Bacterial strains: P. aeruginosa PAO1	ATCC	Cat# 47085
Bacterial strains: P. aeruginosa PA14	Isolated from patient	N/A
Antibodies
Anti‐CRAMP (1‐39) antibody	Innovagen	Cat# PA‐CRPL‐100
Anti‐claudin‐1 antibody	Abcam	Cat# ab180158
Anti‐occludin antibody	Abcam	Cat# ab216327; RRID: AB_2737295
Anti‐zonulin antibody	Abcam	Cat# ab131236; RRID: AB_11157376
Anti‐TRAF6 antibody	Abcam	Cat# ab40675; RRID: AB_778573
Anti‐p65 antibody	Abcam	Cat# ab32536; RRID: AB_776751
Anti‐p‐AKT antibody	Cell Signaling Technology	Cat# 4060; RRID: AB_2315049
Anti‐AKT antibody	Cell Signaling Technology	Cat# 4685; RRID: AB_2225340
Anti‐MyD88 antibody	Cell Signaling Technology	Cat# 4283; RRID: AB_10547882
Anti‐p‐p65 antibody	Cell Signaling Technology	Cat# 3033; RRID: AB_331284
Anti‐ZO‐1 antibody	Thermo Fisher Scientific	Cat# 40‐2200; RRID: AB_2533456
Anti‐ZO‐2 antibody	Thermo Fisher Scientific	Cat# 71‐1400; RRID: AB_88012
Anti‐ACTB antibody	ABclonal	Cat# AC026; RRID: AB_2768234
Alexa Fluor® 700 anti‐mouse CD45	Biolegend	Cat# 103128; RRID: AB_493715
Brilliant Violet® 711 anti‐mouse CD11c	Biolegend	Cat# 117349; RRID: AB_2563905
Brilliant Violet® 605 anti‐mouse CD11b	Biolegend	Cat# 117349; RRID: AB_2563905
APC anti‐mouse CD103	Biolegend	Cat# 12141; RRID: AB_1227503
Brilliant Violet® 421 anti‐mouse CX3CR1	Biolegend	Cat# 149023; RRID: AB_2565706
Brilliant Violet® 421 anti‐mouse CD3e	Biolegend	Cat# 100341; RRID: AB_2562556
PE anti‐mouse CD314 (NKG2D)	Biolegend	Cat# 130207; RRID: AB_1227713
APC anti‐T‐bet	Biolegend	Cat# 644813; RRID: AB_10896913
Alexa Fluor® 488 anti‐mouse FOXP3	Biolegend	Cat# 126405; RRID: AB_1089114
PE anti‐mouse ROR GAMMA (T) (B2D)	Thermo Fisher Scientific	Cat# 12‐6981‐80; RRID: AB_10805392
PE‐Cy™7 anti‐mouse CD4	BD biosciences	Cat# 552775; RRID: AB_394461
anti‐CRAMP pAb	Proteintech	Cat# 12009‐1‐AP; RRID: AB_908736
anti‐E‐cadherin pAb	BD biosciences	Cat# 610181; RRID: AB_397580
anti‐F4/80 mAb	Abcam	Cat# ab6640; RRID: AB_1140040
anti‐Ly6G mAb	Abcam	Cat# ab25377; RRID: AB_470492
CD8a Antibody, Biotin	Miltenyi Biotec	Cat# 130‐118‐147; RRID: AB_2733536
CD11b Antibody, Biotin	Miltenyi Biotec	Cat# 130‐113‐233; RRID: AB_2726044
CD11c Antibody, Biotin	Miltenyi Biotec	Cat# 130‐113‐578; RRID: AB_2726178
CD19 Antibody, Biotin	Miltenyi Biotec	Cat# 130‐113‐729; RRID: AB_2726270
CD45R(B220) Antibody, Biotin	Miltenyi Biotec	Cat# 130‐123‐853; RRID: AB_2819526
CD49b(DX5) Antibody, Biotin	Miltenyi Biotec	Cat# 130‐101‐934; RRID: AB_2660466
CD105 Antibody, Biotin	Miltenyi Biotec	Cat# 130‐101‐992; RRID: AB_2660100
MHC Class II Antibody, Biotin	Miltenyi Biotec	Cat# 130‐101‐849; RRID: AB_2660066
Ter‐119 Antibody, Biotin	Miltenyi Biotec	Cat# 130‐120‐828; RRID: AB_2784480
TCRγ/δ Antibody, Biotin	Miltenyi Biotec	Cat# 130‐114‐028; RRID: AB_2733574
CD25 Antibody, Biotin	Miltenyi Biotec	Cat# 130‐092‐569; RRID: AB_871645
Streptavidin MicroBeads	Miltenyi Biotec	Cat# 130‐048‐101
CD45RB Antibody, FITC	Miltenyi Biotec	Cat# 130‐102‐461; RRID: AB_2658357
Anti‐FITC MicroBeads antibody	Miltenyi Biotec	Cat# 130‐048‐701; RRID: AB_244371
Oligonucleotides and other sequence‐based reagents
PCR primers	This study	Table EV2
Chemicals, Enzymes and other reagents
CRAMP	GL biochem	Cat#088328
Gliadin from wheat	Sigma	Cat#G3375‐25G
Gluten from wheat	Sigma	Cat#G5004‐500G
Software
FlowJo	BD Bioscience	RRID: SCR_008520; https://www.flowjo.com/solutions/flowjo/downloads
GraphPad Prism	GraphPad	RRID: SCR_002798; https://www.graphpad.com/
Image J	Image J	RRID:SCR_003070; https://imagej.en.softonic.com/
R project	R Project	RRID:SCR_001905; https://www.r‐project.org/
FluorChem FC3	ProteinSimple	RRID:SCR_013724; http://www.proteinsimple.com/fluorchem_e.html
ZEN	Zeiss	RRID:SCR_018163; http://stmichaelshospitalresearch.ca/wp‐content/uploads/2015/09/ZEN‐Black‐Quick‐Guide.pdf
Other
Illumina MiSeq	Illumina	RRID:SCR_010233 http://www.illumina.com
CRAMP ELISA kit	My biosource	Cat# MBS7700441
LL‐37 ELISA kit	My biosource	Cat# MBS3800861